following an abbreviated submission:
brivaracetam (Briviact®) is accepted for restricted use within NHSScotland.
Indication under review: Adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in children from 4 years to ≤15 years of age with epilepsy.
SMC restriction: for use in patients with refractory epilepsy and treatment should be initiated by physicians who have appropriate experience in the treatment of epilepsy.
SMC has previously accepted brivaracetam for restricted use as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy.
Download detailed advice439KB (PDF)
- Medicine name:
- brivaracetam (Briviact)
- SMC ID:
- Treatment of partial onset seizures with our without secondary generalisation in children from 4 years of age to 15.
- Pharmaceutical company
- UCB Pharma Ltd
- BNF chapter
- Central nervous system
- Submission type
- Date advice published:
- 10 December 2018